Early treatment with convalescent plasma may reduce risk of

Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing post-COVID conditions -; commonly known as long COVID -; if they receive early treatment with plasma from convalescent (recovered) COVID patients that contain antibodies against SARS-CoV-2, the virus that causes COVID-19.

Related Keywords

United States , American , Megan Craig , Kelly Gebo , David Sullivan , Aaron Tobian , American Society For Microbiology , Transfusion Medicine Division , Johns Hopkins University School Of Medicine , Johns Hopkins Bloomberg School Of Public Health , Johns Hopkins Medicine , Johns Hopkins Bloomberg School , Public Health , American Society , Johns Hopkins University School , Convalescent Plasma , Antibodies , Ntibody , Flood , Chemokines , Clinical Trial , Covid 19 , Ytokine , Ytokines , Health Care , Infectious Diseases , Inflammation , Medicine , Icrobiology , Placebo , Research , Cars , Ars Cov 2 , Virus ,